Biomarin Pharmaceutical Inc (MIL:1BMRN)
€ 70.52 0 (0%) Market Cap: 13.31 Bil Enterprise Value: 13.36 Bil PE Ratio: 70.93 PB Ratio: 2.84 GF Score: 62/100

Biomarin Pharmaceutical Inc at Truist Securities Life Sciences Summit (May Series) Transcript

May 04, 2021 / 05:50PM GMT
Robyn Kay Shelton Karnauskas;Jean<
Truist Securities, Inc., Research Division - Research Analyst

Great. Thank you, everyone, for joining us this afternoon or this morning, depending on where you are. Really excited to have with us for our next fireside chats, BioMarin. From BioMarin, we have J.J. Bienaime, the Chairman and CEO; Brian Mueller, Executive Vice President and CFO. I have a couple of backup people in case -- online. Kripa Devarakonda, one person on my team in case I should disappear, don't worry, the call will go on as planned.

So first, I have to read a disclaimer. Before we begin, I have to read the following. This call is arranged by Truist Securities Research for institutional investors and issuer clients as defined by FINRA. If you're not an institutional investor or issuer, please disconnect at this time. For required disclosures, please see our website at truistsecurities.com or our equity research library.

And with that, I think I'll turn it over to J.J. Thank you both for joining us today. I'll turn it over to you for maybe some opening remarks.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot